

(19)



Europäisches Patentamt

European Patent Office

Office européen des brevets

(11) Publication number:

**0 400 958
A2**

(12)

EUROPEAN PATENT APPLICATION

(21) Application number: 90305819.6

(51) Int. Cl.⁵: **A61K 39/02, A61K 39/112,
C12N 15/31**

(22) Date of filing: 29.05.90

(30) Priority: 30.05.89 GB 8912330

Dundee DD1 4HN Scotland(GB)

(43) Date of publication of application:
05.12.90 Bulletin 90/49

(72) Inventor: **Dougan, Gordan, The Wellcome
Foundation Limited
Langley Court, Beckenham
Kent(GB)**

(64) Designated Contracting States:
AT BE CH DE DK ES FR GB GR IT LI LU NL SE

Inventor: **Chatfield, Steven Neville, The
Wellcome Foundation
Langley Court, Beckenham
Kent(GB)**

(71) Applicant: **THE WELLCOME FOUNDATION
LIMITED
Unicorn House 160 Euston Road
London NW1 2BP(GB)**

Inventor: **Higgins, Christopher Francis,
Imperial Cancer Res.
Fund Lab. Inst. of Mole. Med., John Radcliffe
Hosp
Oxford(GB)**

Applicant: **THE ROYAL SOCIETY
6, Carlton House Terrace
London SW1Y 5AG(GB)**

Inventor: **Dorman, Charles James, The
University Court
The University Court of the University of
Dundee
Scotland(GB)**

Applicant: **THE LISTER INSTITUTE OF
PREVENTIVE MEDICINE Royal National
Orthopaedic Hospital
Brockley Hill
Stanmore Middlesex, HA7 4LP(GB)**

Applicant: **THE UNIVERSITY COURT OF THE
UNIVERSITY OF DUNDEE**

(74) Representative: **Stott, Michael John et al
The Wellcome Research Laboratories Group
Patents & Agreements Langley Court
Beckenham Kent BR3 3BS(GB)**

(54) Live vaccines.

(57) The present invention discloses a novel approach to attenuating bacteria and for their use as live vaccines. The vaccines can be used in human and animal medicine.

In particular, there is disclosed a method of attenuating a bacteria by mutating a gene concerned with the regulation of one or more genes concerned with expression of outer membrane proteins, particularly porin proteins.

EP 0 400 958 A2

LIVE VACCINES

The present invention relates to attenuated microorganisms, to methods for their production, to their use in animal and human medicine and to pharmaceutical compositions containing them.

In 1950 Bacon et al (Br.J.Exp.Path. 31, 714-724) demonstrated that certain auxotrophic mutants of *S.typhi* were attenuated in mice when compared to the parental strain. Certain of these auxotrophic mutants have been proposed as being suitable candidates for the basis of a whole cell vaccine. (See for example Hosieth and Stocker (Nature, 241, 238-39, UK patent application 87/30037, The Wellcome Foundation)).

Together with *envZ*, *ompR* forms a two gene operon, previously designated *ompB*. The nucleotide sequence of this locus is highly conserved between *Escherichia coli* and *Salmonella typhimurium*. The *ompR* gene is primarily concerned with the regulation of osmotically-responsive genes and acts in concert with *envZ*. *ompR* and *envZ* genes form a single transcription unit with translationally -coupled expression (Liljestrom et al., J.Mol.Biol. 201, 663-673 1988). *OmpR* has been identified as a positive activator of gene expression (Jo et al. J.Bacteriol. 140, 843-847; Norioka et al J.Biol.Chem. 261 15252 1986) while *EnvZ* has been shown to be associated with the inner membrane (Forst et al., J.Biol.Chem. 262 16433 1987). It has been proposed that *EnvZ* acts as an environmental sensor and transmits signals to *OmpR*, modulating the transcriptional control activity of the latter (Hall and Silhavy, J.Mol.Biol. 151 1 1981). A pleiotropic mutation in *envZ* has been shown to be suppressed by a mutation in *ompR*, providing genetic evidence that the products of these genes functionally interact (Matsuyama et al., J.Bacteriol 168 1309-1314 1986). Moreover, suppressor mutations of *envZ* have been mapped to *rpoA*, the gene coding for the α subunit of RNA polymerase. This suggests that *OmpR* and RNA polymerase interact (Garrett and Silhavy, J.Bacteriol 169 1379 1987; Matsuyama and Mizushima, J.Mol.Biol. 195 847 1987). The genes which are *ompR* dependent for transcription are primarily those coding for the major outer membrane porins *OmpC* and *OmpF*, although expression of the *S.typhimurium tppB* operon, coding for a tripeptide permease, has been reported to be *OmpR*-dependent (Gibson et al Mol.Gen.Genet. 297 120-129 1987). Binding sites for *OmpR* have been biochemically identified upstream of the *ompC* and *ompF* promoters (Norioka et al., supra). Expression of these genes is reciprocally regulated by growth medium osmolarity in an *OmpR*-dependent manner (Aiba et al., J.Bacteriol 169 3007 1987; Kawaji et al., J.Bacteriol 140 843-847 1979; Mizuno, PNAS(USA) 81 1966-70 1987; van Alphen and Lutenberg, J.Bacteriol 131 625-630 1977). In growth media of high osmolarity, the level of *OmpC* is elevated while that of *OmpF* is repressed; in media of low osmolarity, the reverse is true.

The present inventors have found that it is possible to attenuate pathogenic bacteria by introducing a mutation into a gene which is concerned with the regulation of one or more other genes. In particular the present inventors have found that pathogenic bacteria may be attenuated by introducing a mutation into a gene concerned with the regulation of genes including those encoding for outer membrane proteins.

Thus, according to the present invention there is provided an attenuated bacterium harbouring a mutation in a gene concerned with the regulation of one or more other genes. Preferably the mutation occurs in the *ompR* gene or another gene involved in regulation. There are a large number of other genes which are concerned with regulation and are known to respond to environmental stimuli (Ronson et al Cell 49 579-581). Amongst these the following can be mentioned:

The *ntxB/ntxC* system of *E.coli*, which responds to nitrogen limitation and positively regulates *glnA* and *nifLA* (Buck et al., Nature 320 374-378 1986; Hirschman et al., PNAS 82 7525 1985; Nixon et al., PNAS 83 7850-7854 1986; Reitzer and Magasanik, Cell 45 785 1986); the *phoR/phoB* system of *E.coli* which responds to phosphate limitation (Makino et al., J.Mol.Biol. 192 549-556 1986b); the *cpxA/sfrA* system of *E.coli* which responds to dyes and other toxic compounds (Albin et al., J.Biol.Chem 261 4698 1986; Drury et al, J.Biol.Chem 260 4236-4272 1985). An analogous system in *Rhizobium* is *dctB/dctD*, which is responsive to 4C-dicarboxylic acids (Ronson et al., J.Bacteriol. 169 2424 and Cell 49 579-581 1987). A virulence system of this type has been described in *Agrobacterium*. This is the *virA/virG* system, which responds to plant exudates (Le Roux et al., EMBO J. 6 849-856 1987; Stachel and Zambryski., Am.J.Vet.Res. 45 59-66 1986; Winans et al., PNAS US 83 8278 1986).

The attenuated bacteria, according to the present invention, are preferably Gram-negative bacteria which can invade and grow within eucaryotic cells and colonise the mucosal surface. Examples of these include members of the genera *Salmonella*, *Bordetella*, *Vibrio*, *Haemophilus*, *Escherichia*. In particular the following species can be particularly mentioned; *S.typhi* - the cause of human typhoid; *S.typhimurium* - the cause of salmonellosis in several animal species; *S.enteritidis* - a cause of food poisoning in humans; *S.cholerae-suis* - the cause of salmonellosis in pigs; *Bordetella pertussis* - the cause of whooping cough; *Haemophilus influenzae* - a cause of meningitis; and *Neisseria gonorrhoeae* - the cause of gonorrhoea.

If an attenuated microorganism is to be used in a live form in a vaccine preparation, it is clearly important that such a microorganism does not revert back to the virulent parent. The probability of this happening with a single mutation is considered to be small; however, the risk of reversion occurring in a strain harbouring mutations in two discrete genes, located in different places in the genome, is considered to be insignificant.

The present invention also provides an attenuated bacterium harbouring a first mutation in a regulatory gene and a second mutation in a second gene. Preferably the second gene is a gene encoding for an enzyme involved in an essential biosynthetic pathway, in particular genes involved in the pre-chorismate pathway involved in the biosynthesis of aromatic compounds. The mutations will preferably be in aroA (the gene encoding 5-enolpyruvyl shikimate-3-phosphate synthase), aroC (chorismate synthase) or aroD (3-dehydroquinase).

The attenuated bacteria of the present invention are constructed by the introduction of a stable mutation into the regulatory gene. These mutations may be made by any method known to those skilled in the art. In one embodiment non-reverting mutations were generated by transducing an LT2 ompR::Tn10 marker into S. typhi and S. typhimurium strains. Tn10 transposon carries a gene encoding for tetracycline resistance. Transductants are selected that are tetracycline resistant by growing colonies on an appropriate medium. Further selection is undertaken by screening for those organisms which have lost the tetracycline resistance gene and which derepressed a tpdB::MudI-8 (lac fusion) under anaerobic growth conditions.

Alternative methods for generating non-reverting mutations include cloning the regulatory gene into a vector eg, a plasmid or cosmid and incorporating a selectable marker gene into the cloned gene, at the same time inactivating that gene. A plasmid carrying the inactivated gene and a different selectable marker can be introduced into the organism by known techniques. It is then possible by suitable selection to identify a mutant wherein the inactivated gene has recombined into the organism's own chromosome and the organism's own copy of the gene has been lost. In particular, the vector used is one which is unstable in the organism (ie. a 'suicide' vector) and will be spontaneously lost. The mutated gene on the plasmid and the organism's own copy of the gene on its chromosome may be exchanged by a genetic cross-over event.

Additional methods eliminate the introduction of foreign DNA into vaccine strains at the site of mutations. This can be achieved by cloning the target organism's native gene into a suitable suicide vector (carrying a drug resistance marker) as described above but making a defined deletion in the gene (inactivating it) rather than introducing a selectable marker. This can be introduced into the target organism and the initial selection is made for a single crossover (ie. the organism is drug resistant). Subsequent growth of the strain in the absence of antibiotic and screening of several thousand colonies allows identification of drug sensitive organisms. This may occur in two ways: i) the vector harbouring the deleted gene is lost, ie. the organism is wild type and ii) a second recombination event (resulting in a double crossover) has occurred resulting in the replacement of the wild type gene with the deleted gene. We have developed a novel method for screening for the presence of the deletion using the polymerase chain reaction (PCR). Oligonucleotides are synthesised corresponding to regions either side of the deleted region and are used as primers for PCR to amplify the deleted regions from drug sensitive colonies. The amplified product can be analysed by agarose gel electrophoresis. It is possible to distinguish strains harbouring a deleted region as the PCR product is smaller for the deleted gene than for the wild type gene. The PCR product can also be directly sequenced allowing the deletions to be completely defined.

The strains of the present invention may be genetically engineered so as to express antigens from one or more different pathogens. Such pathogens, maybe viral, bacterial, protozoal or of higher parasitic organisms. The pathogens may infect both humans and other mammals, but maybe species selective, or even species specific. Such strains could then form the basis of a bi or multivalent vaccine. Examples of useful antigens include E. coli heat labile toxin B subunit (LT-B) E. coli K88 antigens, FMDV (Foot and Mouth) peptides, Influenza viral proteins, 69Kd protein from B. pertussis, C fragment from tetanus toxin, C.tetani. Other antigens which could be usefully expressed would be those from Chlamydia, flukes, mycoplasma, roundworms, tapeworms, rabies virus and rotavirus.

These antigens may be produced by the introduction of the gene or genes encoding them into expression cassettes. Expression cassettes will include DNA sequences, in addition to that coding for the structural gene, which will encode for transcriptional and translational initiation and termination regions. The expression cassette may also include regulatory regions. Such expression cassettes are well known in the art and it is well within the skill of the skilled man to construct them. The expression cassette may be a construct or a naturally occurring plasmid. An example of a genetically engineered attenuated Salmonella which expresses a foreign antigen can be found in EP application No. 0 127 153 A (SSVI/Wellcome). The expression cassette may also be engineered to allow the incorporation of the heterologous gene into the bacterial chromosome, making use of the suicide vector and PCR techniques as previously described and

introducing the DNA encoding for foreign antigen into a suitable gene such as *ompR*, *aroA*, *C* or *D*.

A further bivalent vaccine comprising an attenuated *Salmonella typhi*, capable of expressing the *E.coli* heat-labile enterotoxin subunit B was disclosed by Clements et al (Infection and Immunity, 46, No. 2., Nov 1984, p564-569). Ty21a has been used to express other antigens such as the *Shigella sonnei* form I antigen

(Formal et al, Infection and Immunity 34 746-750).

According to a second aspect of the invention there is provided an attenuated bacterium, as herein described, transformed with an expression cassette encoding an antigen of a pathogen, wherein in use said antigen is expressed by said attenuated bacterium.

According to a third aspect of the invention we provide a pharmaceutical composition which comprises attenuated bacteria as herein described in admixture with a pharmaceutically acceptable carrier. Preferably the pharmaceutical composition is a vaccine composition.

The vaccine is advantageously presented in a lyophilised form, for example in a capsular form, for oral administration to a patient. Such capsules may be provided with an enteric coating comprising for example Eudragate "S" Eudragate "L" Cellulose acetate, cellulose phthalate or hydroxy propylmethyl cellulose. These capsules may be used as such, or alternatively, the lyophilised material may be reconstituted prior to administration, e.g. as a suspension. Reconstitution is advantageously effected in a buffer at a suitable pH to ensure the viability of the organisms. In order to protect the attenuated bacteria and the vaccine from gastric acidity, a sodium bicarbonate preparation is advantageously administered before each administration of the vaccine. Alternatively the vaccine may be prepared for parenteral administration, intranasal administration or intramammary.

The present invention also provides a method for the prophylactic treatment of a bacterial infection which comprises administering to a patient an effective dose of the above described vaccine. The dosage employed in such a method of treatment will be dependent on various clinical factors, including the size and weight of the patient, the type of vaccine formulated. However, for attenuated *S. typhi* a dosage comprising the administration of 10^9 to 10^{11} *S. typhi* organisms per dose is generally convenient for a 70kg adult human patient.

In the following, examples are provided of experimental details in accordance with the present invention. It will be understood that these examples are not intended to limit the invention in any way.

Example 1

Construction of *OmpR* mutants in *S.typhimurium*, *S.dublin*.

An *OmpR* deletion was introduced into *S.typhimurium* SL1344, and *S.dublin* using phage P22 (available from Dr. T. Foster, Trinity College, Dublin) transduction. A phage lysate prepared on strain CJD359 was used to transduce all the *Salmonella* strains, selecting for tetracycline-resistant colonies. Strain CJD359 carries Tn10 inserted in the *ompR* gene. In order to ensure that the strains were of the *OmpR* phenotype, P22 lysates were prepared on each strain and used to transduce strain CH776 (available from Prof.C.F.Higgins, ICRF Laboratories, Institute of Molecular Medicine, John Radcliffe Hospital, Oxford, OX3 9DU) which carries a *tpxB::Mud1-8* (lac) fusion. The strain was checked for derepression of the fusion under anaerobic growth conditions after transduction with the P22 lysates. One isolate from each strain was used to prepare tetracycline-sensitive derivatives by selection on Bochner medium. Several of these were purified and checked for the *ompR* deletion using PCR technique described above.

An *S.typhimurium ompR⁻* (BRD 578) strain has been deposited at National Collection of Type Cultures, 61 Colindale Avenue, London, NW9 5HT, UK under No. NCTC 12396 on 25th May 1990. An *S.dublin* (BRD 579) *ompR⁻* strain has been deposited at National Collection of Type Cultures, 61 Colindale Avenue, London, NW9 5HT, UK under No. NCTC 12398 on 25th May 1990.

Example 2

Construction of *aroA OmpR* mutants in *S.typhimurium*, and *S.dublin*.

An *aroA* deletion was introduced into *S.typhimurium* SL1344, and *S.dublin*, using the method of McFarland and Stocker. A phage lysate prepared from strain TT472 (available from Dr. B.A.D. Stocker,

Stanford University, California) was used to transduce all the *Salmonella* strains, selecting for tetracycline-resistant colonies. Strain TT472 carries Tn10 inserted within *serC* which is upstream of and within the same operon as *aroA*. Tetracycline-resistant transductants were aromatic compound, serine and pyridoxine dependent. A second P22 lysate was prepared, grown on SL5254, (available from Dr. B.A.D. Stocker, Stanford University, California) which has a known deletion within *aroA*. This was used to transduce the tetracycline resistant strains which were *serC*⁻ Tn10 and transductants were selected on minimal medium lacking serine and pyridoxine but containing aromatic compounds but in the absence of serine and pyridoxine were tetracycline-sensitive and aromatic compound dependent.

An *OmpR* deletion was then introduced into all the strains using the method described in example 1.
 10 An *S.typhimurium* (BRD 731) *ompR*⁻ *aroA*⁻ strain has been deposited at National Collection of Type Cultures, 61 Colindale Avenue, London, NW9 5HT, UK under No. NCTC 12397 on 25th May 1990. An *S.dublin* (BRD 582) *ompR*⁻ *aroA*⁻ strain has been deposited at National Collection of Type Cultures, 61 Colindale Avenue, London, NW9 5HT, UK under No. NCTC 12399 on 25th May 1990.

15 Example 3

Construction of *Salmonella typhi* *OmpR* mutant

20 An *ompR* deletion was introduced into *S.typhi* Ty2 as described in example 1. In order to ensure that the strain was of the *OmpR* phenotype a P22 lysate was prepared on strain CH776 which carries a *tppB*::*Mud1-8* (lac fusion), and transduced into the *S.typhi* strain. The strain was then tested for derepression of the fusion under anaerobic growth conditions.

25 Example 4

30 Construction of *S.typhi* *aroA ompR* mutant

S.typhi Ty2 *aroA* was prepared as follows: A cosmid bank of *S.typhi* was constructed into λ phage, and used to transduce a well characterised *aroA* mutant of *E.coli*. This facilitated the isolation of an *aroA* clone of *S.typhi*. Subsequent mapping and sequence analysis allowed the identification of convenient restriction sites which were used to construct a defined deletion. The *aroA* gene harbouring the deletion was introduced into the suicide vector gP704 and a method developed for electroporating into *S.typhi*. The drug resistant colonies were grown in the absence of antibiotics and drug sensitive variants isolated. These were screened for their dependence on aromatic compounds for growth in vitro. A colony that was dependent on these compounds for growth was analysed using Southern hybridisation and PCR confirming the deletion in *aroA* and absence of any vector DNA. An *ompR* deletion was introduced into this strain as described in Example 3.

40 *S.typhi* (BRD 732) *ompR*⁻ *aroA*⁻ was deposited at National Collection of Type Cultures, 61 Colindale Avenue, London, UK, under Accession no. NCTC 12395 on 25th May 1990.

45 Example 5

50 Comparison of attenuation *Salmonella typhimurium* CJD 359 (*ompR*) with virulent parent strain, *Salmonella typhimurium* SL 1344.

The CJD359 strain (now BRD 578) was constructed using transposon-linked mutations into *S.typhimurium* SL1344 using bacteriophage P22-mediated transduction, as described in Example 1.

55 Infection of mice and enumeration of bacteria in murine organs.

BALB/c males of 8-10 weeks of age were used throughout, bred in the animal unit at Wellcome

Research Laboratories from breeders originally purchased for OLAC (1976) UK Ltd (Black, Bicester, Oxfordshire, UK). Livers, spleens, mesenteric lymph nodes and Peyer's patches were homogenised as previously described, Mashell et al 1987 Microb.Pathogen, 3 129-141. Viable counts were performed on these homogenates using L-agar as growth medium. Counts are shown in the figures as geometric means \pm standard errors (n=4 mice per point). For oral inoculation into mice bacteria were grown statically at 37°C overnight in 2 litres of L-broth. The culture was centrifuged and the bacterial pellet was resuspended in its own volume and diluted in phosphate buffered salines (pH 7.2) as required. Bacteria in 0.2ml were administered in 0.2ml volumes orally to lightly anaesthetised mice by gavage needle. The inoculum was calculated by plating appropriate dilutions on L-agar pour plates. For intravenous (iv.) inoculation, mice were injected with 0.2ml of bacterial suspension into the tail vein. Deaths were recorded over the following four weeks and the LD₅₀ was calculated by the method of Reed and Muench 1938 Am.J.Hyg, 27, 493-497.

After oral administration CJD359 had an LD₅₀ of greater 9.64 log units as compared to the parental strain, SL 1344, which has an LD₅₀ of 6.38 log units. (All LD₅₀ were calculated after 28 days). Thus CJD359 is highly attenuated. After iv. administration CJD359 had an iv. LD₅₀ of Log 5.13 compared to < Log 10 for SL1344 and we again conclude that CJD359 is highly attenuated compared to SL1344.

In vivo growth pattern of CJD359 after oral and iv administration to BALB/c mice.

The ability of SL1344 and CJD359 to grow in vivo after oral or iv administration was assessed. For the iv experiment the numbers of viable organisms in the livers and spleens at different days after challenge were assessed (Fig 1a). After iv administration of Log 3.7 SL1344 the strain grew rapidly in livers and spleen and all mice died within seven days of challenge. After administration iv of Log 4.2 CJD359 a level of about 10% of the inoculum was detected in the livers and spleens 24 hours later. After this initial drop CJD359 appeared to grow slowly reaching a maximal level of about Log 5 organisms by day 14 and was then slowly cleared. All mice challenged iv with CJD359 exhibited a pronounced splenomegaly during the early phases of the infection. Log 9.8 SL1344 and Log 9.5 CJD359 organisms were administered orally to BALB/c mice and the levels of organisms were assessed in livers, spleens, peyers patches and mesenteric lymph nodes at different times after challenge. Again CJD359 exhibited an impaired ability to grow in vivo compared to SL1344 (Fig 1b). SL1344 invaded the tissues of all mice challenged and grew rapidly until all mice had died within 14 days of challenge. CJD359 was also able to invade and organisms were detected in peyers patches and mesenteric lymph nodes by day 1 post challenge. By day 4 bacteria had reached liver and spleen and attained a maximal level of colonisation of the host tissue around day 7. Thereafter CJD359 was slowly cleared from the tissues.

Protection of mice after oral challenge.

Mice were immunised with Log 10¹⁰ CJD359 and challenged 28 days later with the virulent parental strain SL1344. Mice vaccinated with CJD359 showed excellent protection against challenge with SL1344. The LD₅₀ in immunised animals was >Log 9.64 compared with Log 5.64 for unimmunised controls. Thus mice vaccinated orally with CJD359 were well protected against virulent SL1344 challenge.

Example 6: Formulation

An attenuated bacterium of the present invention is preferably presented in oral tablet form.

Ingredient	mg/tablet
Core-tablets	
1) Freeze-dried excipient carrier containing 10^9 - 10^{10} attenuated bacteria 2) Silica dioxide (Aerosil 200) 3) Dipac (97% sucrose) 4) Cross-linked Povidone (Kollidon CL) 5) Microcrystalline Cellulose (Avicel pH 102) 6. Magnesium Stearate	70.0 0.5 235.0 7.0 35.0 2.5 <u>350.0</u>
Coating	
7) Opadry Enteric, OY-P-7156 (Polyvinyl acetate phthalate + Diethylphthate)	35.0 <u>385.0</u>

A carrier containing 5% sucrose 1% sodium glutamate and 1% bacto casitone in an aqueous solvent is prepared. The organisms are suspended in this carrier and then subjected to freeze-drying.

The freeze-dried material is blended with Aerosil 200 and the blended mixture is sifted through a screen. The sifted powder is mixed with Dipac, Kollidan CL, Aricel pH 102 and Magnesium Stearate in a blender. This blend is compressed into tablets for subsequent enteric coatings.

The skilled man will appreciate that many of the ingredients in this formulation could be replaced by functionally equivalent pharmaceutically acceptable excipients.

Claims

Claims for the following Contracting State: EP

1. An attenuated bacteria harbouring a mutation in a gene concerned with the regulation of one or more genes.
2. An attenuated bacteria as claimed in claim 1 harbouring a mutation in a gene concerned with the regulation of a gene encoding an outer membrane protein.
3. An attenuated bacteria as claimed in claim 1 or 2 harbouring a mutation in a gene concerned with the regulation of a porin gene.
4. An attenuated bacteria as claimed in any one of claims 1 to 3 harbouring a mutation in the gene designated ompR.
5. An attenuated bacteria as claimed in any preceding claim which is a gram negative bacteria.
6. An attenuated bacteria as claimed in any preceding claim which is selected from the genera Salmonella, Bordetella, Vibrio, Haemophilus and Escherichia.
7. An attenuated bacteria as claimed in any preceding claim which is selected from S.typhi, S.typhimurium, S.enteritidis, S.cholerae-suis, Bordetella pertussis, Haemophilus influenzae and Neisseria gonorrhoeae.
8. An attenuated bacteria as claimed in any preceding claim which is selected from S.typhi ompR⁻.
9. An attenuated bacteria as claimed in any preceding claim which is selected from S.typhi aroA⁻ ompR⁻.
10. An attenuated bacteria as claimed in any preceding claim which is selected from S.typhimurium ompR⁻ or S.typhimurium aroA⁻ ompR⁻.
11. An attenuated bacteria as claimed in any preceding claim which is selected from S.dublin ompR⁻ or S.dublin aroA⁻ ompR⁻.
12. A bacteria as claimed in any one of claims 1 to 12 additionally harbouring a mutation in a second gene.
13. A bacteria as claimed in claim 12 wherein the second mutation is in a gene encoding for an enzyme involved in an essential auxotrophic pathway.
14. A bacteria as claimed in claim 12 or 13 wherein the second mutation occurs in an enzyme encoding for a gene in the bacteria's aromatic pathway.

15. A bacteria as claimed in any one of claims 12 to 14 wherein the the second mutation occurs in one of aroA, aroC, aroD genes.
16. A bacteria as claimed in any one of claims 1 to 15 transformed with an expression cassette encoding a gene encoding an antigen from a heterologous pathogen.
17. A pharmaceutical formulation comprising a bacteria as claimed in any one of claims 1 to 16 in admixture with a pharmaceutically acceptable excipient.
18. A bacteria as claimed in any one of claims 1 to 16 for use in medical therapy.
19. A method of attenuating a bacteria as claimed in any one of claims 1 to 16 comprising introducing into a virulent strain a mutation into a gene concerned with the regulation of one or more genes.
20. A method of attenuating a bacteria as claimed in any one of claims 12 to 15 comprising introducing into a virulent strain two mutations, one of the mutations being in a gene concerned with regulation of one or more genes.
21. A method as claimed in claim 19 or 20 wherein a mutation is introduced by transposon mutagenesis.
22. A method as claimed in claim 19 or 20 wherein a mutation is introduced via a suicide vector.
23. A method as claimed in claim 19 or 20 wherein the mutation introduced into the gene is achieved by introducing into the gene, a gene encoding for a heterologous protein.
1. A process for attenuating a bacteria comprising introducing a mutation into a gene concerned with the regulation of one or more genes.
2. A process for attenuating a bacteria as claimed in claim 1 wherein the gene is concerned with the regulation of an outer membrane protein.
3. A process as claimed in claim 1 or 2 wherein the gene is concerned with the regulation of a porin gene.
4. A process as claimed in claims 1, 2 or 3 wherein the bacteria is a gram-negative bacteria.
5. A process as claimed in any preceding claim wherein the bacteria is selected from the genera Salmonella, Bordetella, Vibrio, Haemophilus and Escherichia.
6. A process as claimed in any preceding claim wherein the gene is ompR.
7. A process as claimed in any preceding claim wherein the bacteria is selected from S.typhi, S.typhimurium, S.enteritidis, S.cholerae-suis, Bordetella pertussis, Haemophilus influenzae and Neisseria gonorrhoeae.
8. A process as claimed in any preceding claim wherein the bacteria is selected from S.typhi ompR⁻.
9. A process as claimed in any preceding claim wherein the bacteria is selected from S.typhi aroA⁻ ompR⁻.
10. A process as claimed in any preceding claim wherein the bacteria is selected from S.typhimurium ompR⁻ or S.typhimurium aroA⁻ ompR⁻.
11. A process as claimed in any preceding claim wherein the bacteria is selected from S.dublin ompR⁻ or S.dublin aroA⁻ ompR⁻.
12. A process as claimed in any preceding claim wherein a mutation is introduced into a second gene.
13. A process as claimed in claim 12 wherein the second mutation is introduced in one of aroA, aroC or aroE gene.
14. A process as claimed in any one of claims 1-13 wherein the bacteria is transformed with an expression cassette encoding a heterologous protein.
15. A process as claimed in any preceding claim wherein a mutation is introduced by transposon mutagenesis.
16. A method as claimed in any one of claims 1 to 14 wherein a mutation is introduced via a suicide vector.
17. A method as claimed in any one of claims 1 to 14 wherein the mutation into the gene is achieved by introducing into the gene a gene encoding for a heterologous protein.

Fig.1(a).





Fig.1(b).





Europäisches Patentamt
European Patent Office
Office européen des brevets



Publication number: **0 400 958 A3**

(12)

EUROPEAN PATENT APPLICATION

(21) Application number: 90305819.6

(51) Int. Cl.5: **A61K 39/02, A61K 39/112, C12N 15/31**

(22) Date of filing: 29.05.90

(30) Priority: 30.05.89 GB 8912330

(43) Date of publication of application:
05.12.90 Bulletin 90/49

(84) Designated Contracting States:
AT BE CH DE DK ES FR GB GR IT LI LU NL SE

(88) Date of deferred publication of the search report:
18.09.91 Bulletin 91/38

(71) Applicant: **THE WELLCOME FOUNDATION LIMITED**
Unicorn House 160 Euston Road
London NW1 2BP(GB).

Applicant: **THE ROYAL SOCIETY**
6, Carlton House Terrace
London SW1Y 5AG(GB)

Applicant: **THE LISTER INSTITUTE OF PREVENTIVE MEDICINE** Royal National
Orthopaedic Hospital
Brockley Hill
Stanmore Middlesex, HA7 4LP(GB)

Applicant: **THE UNIVERSITY OF DUNDEE,**

UNIVERSITY COURT

Dundee DD1 4HN Scotland(GB)

(72) Inventor: **Dougan, Gordon, The Wellcome Foundation Limited**
Langley Court, Beckenham
Kent(GB)

Inventor: **Chatfield, Steven Neville, The Wellcome Foundation**
Langley Court, Beckenham
Kent(GB)

Inventor: **Higgins, Christopher Francis, Imperial Cancer Res. Fund Lab. Inst. of Mole. Med., John Radcliffe Hosp**
Oxford(GB)

Inventor: **Dorman, Charles James, The University Court**
The University Court of the University of Dundee
Scotland(GB)

(74) Representative: **Stott, Michael John et al**
The Wellcome Research Laboratories Group
Patents & Agreements Langley Court
Beckenham Kent BR3 3BS(GB)

(54) Live vaccines.

(57) The present invention discloses a novel approach to attenuating bacteria and for their use as live vaccines. The vaccines can be used in human and animal medicine.

In particular, there is disclosed a method of attenuating a bacteria by mutating a gene concerned with the regulation of one or more genes concerned with expression of outer membrane proteins, particularly porin proteins.

EP 0 400 958 A3



European
Patent Office

EUROPEAN SEARCH REPORT

Application Number

EP 90 30 5819

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int. Cl.5)
X	PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA vol. 83, no. 21, November 1986, pages 8278-8282, Washington DC, US; S.C. WINANS et al.: "A gene essential for Agrobacterium virulence is homologous to a family of positive regulatory loci" * whole article *	1-4,14-17	A 61 K 39/02 A 61 K 39/112 C 12 N 15/31
Y	idem ---	5-7,10	
X	MOL. GEN. GENET. vol. 188, no. 2, 1982, pages 184-189, DE; P. LILJESTROEM et al.: "Cloning of the Regulatory Locus ompB of Salmonella typhimurium LT-2. I. Isolation of the ompR Gene and Identification of Its Gene Product" * whole article; in particular table 1 *	1-7,10, 14-17	
D,Y	JOURNAL OF MOLECULAR BIOLOGY vol. 201, no. 4, 20 June 1988, pages 663-673, London, GB; P. LILJESTROEM et al.: "Structure and Expression of the ompB Operon, the Regulatory Locus for the Outer Membrane Porin Regulon in Salmonella typhimurium LT-2" * whole article *	5-7,10	
Y	GB-A-2 076 287 (RAMOT UNIVERSITY et al.) * whole document *	1-6,15	
Y	MOL. GEN. GENET. vol. 203, no. 3, 1986, pages 520-523, DE; M. PIRHONEN et al.: "In vivo cloning and characterization of mutations of the regulatory locus ompR of Escherichia coli K 12" * whole article; in particular table 1 *	1-6,15	

		-/-	
The present search report has been drawn up for all claims			
Place of search		Date of completion of search	Examiner
Berlin		28 May 91	JULIA P.
CATEGORY OF CITED DOCUMENTS X: particularly relevant if taken alone Y: particularly relevant if combined with another document of the same category A: technological background O: non-written disclosure P: intermediate document T: theory or principle underlying the invention E: earlier patent document, but published on, or after the filing date D: document cited in the application L: document cited for other reasons B: member of the same patent family, corresponding document			



European
Patent Office

EUROPEAN SEARCH REPORT

Page 2

Application Number

EP 90 30 5819

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int. Cl.5)
A	EP-A-0 184 086 (THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY) * whole document *	4,5,7, 12-15,17	
P,X	WO-A-8 909 616 (SYMBICOM AB) * abstract; page 6, lines 9-23; page 7, line 1 - page 9, line 7 *	1,4,5,14, 15,17	
P,X	INFECTION AND IMMUNITY vol. 57, no. 7, July 1989, pages 2136-2140, US; C.J. DORMAN et al.: "Characterization of Porin and ompR Mutants of a Virulent Strain of Salmonella typhimurium: ompR Mutants Are Attenuated In Vivo" * whole article *	1-7,10,15	
P,X	PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA vol. 86, no. 18, September 1989, pages 7077-7081, Washington DC, US; E.A. GROISMAN et al.: "Salmonella typhimurium phoP virulence gene is a transcriptional regulator" * whole article *	1-7,15	
X	MOL. GEN. GENET. vol. 211, no. 3, 1988, pages 538-540, DE; K. IKENAKA et al.: "A dominant mutation in Escherichia coli OmpR lies within a domain which is highly conserved in a large family of bacterial regulatory proteins" * whole article *	1-6	TECHNICAL FIELDS SEARCHED (Int. Cl.5)
T	JOURNAL OF BACTERIOLOGY vol. 172, no. 11, November 1990, pages 6274-6481, US; M.L. BERNARDINI et al.: "The Two-Component Regulatory System OmpR-EnvZ Controls the Virulence of Shigella flexneri" * whole article *	1-4,6,14, 15,17	
The present search report has been drawn up for all claims			
Place of search Berlin		Date of completion of search 28 May 91	Examiner JULIA P.
CATEGORY OF CITED DOCUMENTS X: particularly relevant if taken alone Y: particularly relevant if combined with another document of the same category A: technological background O: non-written disclosure P: intermediate document T: theory or principle underlying the invention E: earlier patent document, but published on, or after the filing date D: document cited in the application L: document cited for other reasons &: member of the same patent family, corresponding document			

